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1. Introduction 
	  
1.1 Early growth response – 1 
	  
1.1.1 The Egr-1 gene and protein product 
 
The transcription factor Early growth response – 1 (Egr-1) was discovered 
independently by several research laboratories and has been described by 
many different terms. Egr-1 was found first in human lymphocytes 
treated with concanavalin-A and cyclohexamide as a suspected regulatory 
cell cycle gene and was called G0S30 (Forsdyke 1985). Later, Milbrandt 
referred to the transcription factor as NGF inducible A (NGFI-A) due to its 
discovery after the stimulation of neuronal cells with nerve growth factor 
(NGF) (Milbrandt 1987). Other terms to describe Egr-1 include Zif268 
(Zincfinger 268) (Christy and Nathans 1989), Krox24 (Krüppel Box 24) 
(Lemaire, Revelant et al. 1988), TIS8 (tetradecanoyl phorbol acetate-
inducible sequence 8) (Lim, Varnum et al. 1987) CEF-5 (chicken embryo 
fibroblasts-5) (Simmons, Levy et al. 1989) and ZENK (zif-268; egr-1; 
NGFI-A; Krox-24) (Mello, Vicario et al. 1992). The current name Early 
growth response -1 (Egr-1) was first coined in 1988 by Sukhatme and 
Cao (Sukhatme, Cao et al. 1988). Soon after its discovery, the gene locus 
was mapped to human chromosome 5q23-31 (Sukhatme, Cao et al. 
1988). 
Within the 700 base pairs full length promoter region, located 5’ upstream 
of the Egr-1-gene, five serum response elements (SRE) (Tsai-Morris, Cao 
et al. 1988) were identified, which account not only for the serum induced 
transcription, but also for the radioinducibility of Egr-1. All of those SRE 
sites contain the consensus sequence CC(A/T)GG, also known as ‘CArG’ 
element (Meyer, Kupper et al. 2002). Other regulatory elements identified 
within the promoter sequence are two cAMP responsive elements (CRE), 
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an activated protein-1/thiophorbolester responsive element (AP-1/TRE) 
(Meyer, Kupper et al. 2002) and two Egr-1 binding sequence (EBS) 
regions, which are thought to allow Egr-1 to regulate its own transcription 
(Cao, Mahendran et al. 1993). A schematic drawing of regulatory 
elements within the Egr-1 promoter sequence is shown in figure 1. 
 
Figure 1: Schematic drawing representing the Egr-1 promoter 
sequence with regulatory elements: The human full-length Egr-1 
promoter (700 bp) contains upstream of the TATA box two serum 
response elements (SRE 4, 5), flanked by one cAMP responsive element 
on each side(CRE 1, 2). Three more serum response elements (SRE 1-3), 
two Egr-1 binding sequences and activated protein-1 responsive element 
(AP 1) are mapped further upstream (adapted from (Meyer, Kupper et al. 
2002)) 
 
Egr-1 mRNA kinetics were observed in various cell types after exposure to 
diverse activation stimuli. The transcripts are induced between 30 min 
and 1 h after cell activation and decline to basal concentration at 2 h 
(Keeton, Bortoff et al. 2003). Egr-1 protein kinetics were observed to 
follow the mRNA induction pattern with a 1 – 2 h delay. It was found that 
Egr-1 protein levels in vivo increase within 20 min, continue to be 
elevated at 1 to 2 h and descend back to basic levels by 4 h to 8 h (Cao, 
Koski et al. 1990; O'Donovan, Wilkens et al. 1998). 
The Egr-1 gene encodes a 533-amino acid nuclear phosphoprotein (Lim, 
Varnum et al. 1987; Milbrandt 1987; Sukhatme, Cao et al. 1988), which 
belongs to the Egr family (Egr-1 to 4) of zinc finger proteins (Kharbanda, 
Nakamura et al. 1991; Patwardhan, Gashler et al. 1991). The three 
dimensional crystal structure of the Egr-1 protein was first shown by 
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Pavletich and Pabo (Pavletich and Pabo 1991). Later, it was revealed that 
the nuclear phosphoprotein product of Egr-1 contains three zinc fingers of 
the Cys2His2 class, which bind to their target DNA sequence 5’-
CGCCCCCGC-3’ in a zinc dependent manner (Cao, Koski et al. 1990; 
Gashler, Swaminathan et al. 1993). Each zinc finger domain consists of 
an alpha helix and an anti-parallel beta-pleated sheet. A representation of 
the protein structure of the Egr-1 zinc finger-DNA complex is shown in 
figure 2. 
 
 
Figure 2: The protein structure of Zif 268 (Egr-1) Zinc Finger – 
DNA Complex, PDB-ID 1AAY, visualized from X-ray diffraction (Elrod-
Erickson, Rould et al. 1996) 
 
A bipartite nuclear localization signal (NLS) of Egr-1 was identified to 
reside within the basic residues 315 to 330 of the N-terminal sequence in 
addition to the second or third zinc finger (Gashler, Swaminathan et al. 
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1993), thus making the NLS dependent on the structure of the DNA 
binding domain (Matheny, Day et al. 1994). 
The transcriptional co-repressors Nab 1 (NGFI-A binding protein 1) and 
Nab 2 have been found to have regulatory functions on Egr-1 by inhibiting 
its activity via direct protein - protein interaction. It was shown that this 
interaction is located within the central domain of the Egr-1 protein, which 
is presumably located within the residues 270 – 296 (Russo, Sevetson et 
al. 1995; Swirnoff, Apel et al. 1998). The modular structure of Egr-1 is 
represented in figure 3. 
 
Figure 3: Modular structure of the zinc finger transcription factor 
Egr-1. The Egr-1 protein contains a transcriptional activation domain on 
the N-terminus followed by an inhibitory domain functioning as binding 
site for the transcriptional co-repressors Nab-1 and Nab-2. The DNA-
binding domain consists of three zinc finger motifs. (adapted from (Thiel 
and Cibelli 2002)). 
 
While Nab-1 is expressed constitutively, Nab-2 expression is induced by 
some of the same stimuli that also increase Egr-1 expression, such as 
serum or NGF stimulation (Svaren, Sevetson et al. 1996) and thereby 
prevents excessive activation of the Egr-1 target promoter. Additionally, 
Nab 2 is thought to be involved in a negative feedback loop, since Egr-1 
itself is able to induce the expression of Nab 2 (Kumbrink, Gerlinger et al. 
2005; Kumbrink, Kirsch et al. 2010). 
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Besides NGF, FGF1 (fibroblast growth factor 1), PDGF (platelet derived 
growth factor), VEGF (vascular endothelial growth factor), CBP (cAMP 
response element binding protein), p300 (Silverman, Du et al. 1998) and 
many other stimuli such as growth and differentiation factors, hormones, 
neurotransmitters, cytotoxic metabolites, cytokines, hypoxia (Yan, Lu et 
al. 1999), reactive oxygen intermediates and ionizing radiation (Datta, 
Taneja et al. 1993), UV radiation, death signals, tissue injury (Gashler 
and Sukhatme 1995; Thiel and Cibelli 2002) and other general serum 
proteins are also capable of activating Egr-1 (for a recent review see 
(J.I.Pagel 2010)) 
 
1.1.2 Egr-1 role and functions 
 
Egr-1 is an important activator of a great number of target genes, which 
in turn are key players in differentiation, apoptosis and mitogenesis (Thiel 
and Cibelli 2002; Lee, Cho et al. 2004; Abdel-Malak, Mofarrahi et al. 
2009). Being in the crossfire of different growth signals makes Egr-1 an 
interesting candidate to be studied during embryogenesis and neonatal 
development. Indeed Egr-1 activity has been detected in bones, whisker 
pads and teeth of developing mice embryos (McMahon, Champion et al. 
1990). 
To study the functions of Egr-1 in detail, Egr-1 knockout mice have been 
developed (Lee, Tourtellotte et al. 1995; Lee, Wang et al. 1996). 
Although Egr-1 knockout mice are viable, the females are sterile due to 
luteinizing hormone deficiency (Lee, Sadovsky et al. 1996; Topilko, 
Schneider-Maunoury et al. 1998; Tremblay and Drouin 1999). 
Egr-1 has been shown to play an important role in an array of diverse 
physiological processes, such as the cholesterol biosynthesis in liver 
(Gokey, Lopez-Anido et al. 2011), the regulation of synaptic plasticity and 
long term memory formation (Jones, Errington et al. 2001; James, 
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Conway et al. 2006; Maddox, Monsey et al. 2011), reproduction (Topilko, 
Schneider-Maunoury et al. 1998), wound healing (Wu, Melichian et al. 
2009), bone repair (Reumann, Strachna et al. 2011; Reumann, Strachna 
et al. 2011), persistent inflammatory pain (Ko, Vadakkan et al. 2005), or 
tissue survival following hypoxia (Yan, Lu et al. 1999; Nishi, Nishi et al. 
2002). 
A large amount of evidence for a crucial role of Egr-1 in the regulation of 
the immune response has also been found (McMahon and Monroe 1996) 
and binding sites within the promoter regions of genes coding for immune 
response proteins have been identified for TNFα (tumor necrosis factor 
α)(Kramer, Meichle et al. 1994), ICAM-1 (intercellular adhesion molecule 
1) (Maltzman, Carmen et al. 1996), metallo-proteinases (Haas, Stitelman 
et al. 1999) and others. Moreover, the secretion of inflammatory 
mediators, such as Il-8, Il-13 or MMP-2 (matrix metalloproteinase – 2) 
from activated immune cells has been shown to rely on Egr-1 dependent 
mechanisms (Cho, Kang et al. 2006; Li, Ning et al. 2007; Ning, Dong et al. 
2007). 
Besides physiological processes, Egr-1 has been associated with a 
multitude of pathogenic processes, such as atherosclerosis (McCaffrey, Fu 
et al. 2000; Blaschke, Bruemmer et al. 2004), COPD (chronic obstructive 
pulmonary disease) (Shen, Gong et al. 2011), ALI (acute lung injury) 
(Copland, Kavanagh et al. 2003), diabetes (Hasan, Alshuaib et al. 2003; 
Hasan, Phukan et al. 2003), Alzheimer disease (Lu, Li et al. 2011), 
myopia (Schippert, Burkhardt et al. 2007), numerous viral infections 
(human immunodeficiency virus 1 (HIV-1) (Fan, Zou et al. 2011), mouse 
hepatitis virus (MHV) (Cai, Liu et al. 2006), herpes simplex virus-1 (HSV-
1) (Bedadala, Palem et al. 2011)) or ethanol-induced fatty liver injury 
(McMullen, Pritchard et al. 2005). In addition, Egr-1 seems to be involved 
in tumor growth (Yang and Abdulkadir 2003) and was suggested to play 
various roles in neoplastic processes, such as colon carcinoma 
(Mahalingam, Natoni et al. 2010), gastric carcinoma (Zheng, Pu et al. 
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2010), lung carcinoma (Shimoyamada, Yazawa et al. 2010) or prostate 
carcinoma (Yang and Abdulkadir 2003). 
In summary, recent research clearly showed that Egr-1 seems to play a 
central role in a multitude of diverse physiological and pathological 
processes alike and thus is an important gene to be studied. 
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1.2 The firefly luciferase 
 
1.2.1 The luciferase (luc) gene and protein product 
 
The firefly luciferase gene originates from the North-American firefly 
Photinus pyralis (Fig 4A) and consists of six introns, each less than sixty 
bases in length (de Wet, Wood et al. 1987). Its protein produces 
bioluminescence by catalyzing a light producing chemical reaction. The 
luciferase protein has a molecular weight of 62 kDa and contains an 
active site comprised of two separated domains: the larger first part is 
located at the N-terminal domain (residues 4 - 436) and the smaller 
second part at the C-terminal domain (residues 440 - 544)(Conti, Franks 
et al. 1996). The three dimensional protein structure was revealed by 
Conti and Franks (Conti, Franks et al. 1996) and is shown in figure 4B. 
 
Figure 4: The firefly Photinus pyralis and the firefly luciferase 
A The bioluminescent organism Photinus pyralis (adapted from 
(Rowe, Dikici et al. 2009)) 
B The protein structure of luciferase, visualized from X-ray 
crystallography (Conti, Franks et al. 1996) 
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The luciferase protein is found predominantly within the peroxisomes of 
cells due to a peroxisomal targeting signal, which is located at its extreme 
C-terminus (Gould, Keller et al. 1987). 
The luciferase catalyzes the reaction of its unique substrate, named firefly 
luciferin. Luciferin is a benzthiazole and naturally only occurs in Photinus 
and Luciola fireflies (Greer and Szalay 2002). Biochemically, the firefly 
luciferase protein functions like a monooxygenase and catalyzes a two-
step reaction: The reversible first step requires in addition to luciferin, 
ATP and magnesium and forms an enzyme bound luciferyl-adenylate. In 
the second step, the luciferyl-adenylate undergoes an oxidative 
decarboxylation using molecular oxygen. This results in the formation of 
carbon dioxide, oxyluciferin, AMP and light. The overall reaction is shown 
in figure 5. 
 
Figure 5: Light emitting reaction of the Photinus pyralis luciferase 
protein. The reaction depends on the cofactor Mg2+, O2 and ATP (adapted 
from (Waidmann, Bleichrodt et al. 2011)) 
 
The wavelength of emitted light is pH sensitive: At a pH 7.5 to 8.5, 
yellow-green with peak emission at 560 nm is emitted (de Wet, Wood et 
al. 1987), while the spectrum is shifted towards red at a more acidic pH in 
vitro (Viviani, Oehlmeyer et al. 2005). The pH dependent spectral 
changes are represented in figure 6. 
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Figure 6: Bioluminescence spectra of Photinus pyralis luciferase at 
pH 6, pH 7 and pH 8 (adapted from (Viviani, Oehlmeyer et al. 2005)). 
 
Mammalian cells can express the luciferase protein product after its gene 
has been incorporated into the cells genome. After exogenous addition of 
its substrate D-luciferin, which is rapidly distributed throughout the entire 
organism, bioluminescence of luciferases expressing cells with light in the 
wavelength range of 400-620 nm, at an emissions peak at 560 nm, can 
be observed (Rice, Cable et al. 2001; Ray, Pimenta et al. 2002). 
 
1.2.2 Applications of luciferase 
 
The nocturnal organism of Photinus pyralis uses its bioluminescence 
apparatus to emit specific light signals to communicate the species and 
sex of the signaler for mating purposes (Stanger-Hall, Lloyd et al. 2007). 
A multitude of scientific uses of firefly luciferases have emerged in recent 
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years. Through the use of luciferases, e.g. a widely spread standard assay 
to detect the presence of ATP or magnesium (Dumollard, Marangos et al. 
2004) has been developed. 
Firefly luciferases have also been proven to be a useful non-invasive tool 
for monitoring infections and drug treatment in living animals by the use 
of bioluminescent bacteria and viruses. Examples include the evaluation 
of antibiotic therapy on E. coli bacteria in a cutaneous wound model 
(Jawhara and Mordon 2004) and the study of intestinal colonization by E. 
coli (Foucault, Thomas et al. 2010), drug efficiency testing and in vivo 
monitoring of invasive Aspergillosis (Brock, Jouvion et al. 2008) or 
monitoring of herpes simplex virus type 1 (HSV-1) infection and therapy 
(Luker, Bardill et al. 2002). 
Other applications include the monitoring of protein-protein interactions 
through the use of a split luciferase enzyme in living mice (Paulmurugan, 
Umezawa et al. 2002; Zhang 2004), together with luciferase 
complementation imaging (LCI) and bioluminescent optical imaging (Ray, 
Pimenta et al. 2002; Luker and Piwnica-Worms 2004).  
Molecular imaging using luciferases has become a useful tool to 
continuously observe in vivo gene expression in human embryonic stem 
cells over a period of several weeks (Wilson, Yu et al. 2008) or the in vivo 
tracking of cells in cancer through vector-mediated gene expression 
(Shah, Jacobs et al. 2004). 
Additionally, the firefly luciferase has been successfully utilized as a 
bioluminescent reporter in living mice using a photon imaging system for 
the noninvasive in vivo study of gene induction (Contag, Spilman et al. 
1997) or the in vivo monitoring of circadian rhythms (Wilsbacher, 
Yamazaki et al. 2002). 
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In recent decades, luciferase imaging has been proven to be a useful tool 
for non-invasive monitoring of biologic processes not only in cell and 
tissue cultures, but also in living, multi-cellular organisms. 
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1.3 The Egr-luc mouse model 
 
Previously, a transgenic mouse model using the murine full length Egr-1 
promoter sequence to control the expression of the luciferase reporter 
was created in our lab. The construct containing the sequence from -930 
to +237 base pairs relative to the Egr-1 promoter transcriptional start site 
of the murine Egr-1 promoter coupled to the reporter gene luciferase, was 
microinjected into the male pronucleus of mouse zygotes and was 
transferred into pseudo-pregnant females of C57Bl6 background. A 
schematic drawing of the construct used for generating Egr-luc transgenic 
mice is shown in figure 7. Presence of the transgene was confirmed by 
PCR analysis (Primer combination of the sequence between the luciferases 
gene and the SV40 small-t intron) (Vogel 2003). 
 
Figure 7: Schematic drawing of the construct used for generating 
transgenic mice: The murine full-length Egr-1 promoter (1200 bp) was 
linked to the reporter gene luciferase followed by the SV40 small-t intron 
(adapted from (Vogel 2003)). 
 
Seven founder animals were obtained from this construct and breeding 
with wild-type animals of C57Bl6 strain yielded the establishments of two 
lines (L1 and L2) that were further propagated. All Egr-1-luc transgenic 
mice were healthy and viable with a normal life span with no display of 
any malformations in consequence of the presence of the transgene 
(Vogel 2003). 
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1.4 Rationality of the studies 
 
Most data on Egr-1 gene activation have been evaluated only within in 
vitro studies and could not be confirmed when reevaluated in vivo 
(J.I.Pagel 2010). For this reason, it is inevitably necessary to study 
activation patterns and their time course in the living organism. In 
knockout mice, however, the relatively mild phenotype suggests that 
compensation of Egr-1 loss of function by other Egr family members 
cannot be excluded. Moreover, Egr-1 activation is subject of rapid 
alteration due to its sensitivity to many external stimuli. Transcriptional 
modifications are easily prone to external and environmental 
manipulations, including growth and differentiation factors, hormones, 
neurotransmitters, cytotoxic metabolites, cytokines, hypoxia, UV radiation, 
death signals or tissue injury (Gashler and Sukhatme 1995; Thiel and 
Cibelli 2002). This suggests that Egr-1 could possibly also be induced 
without intention by the investigator and dynamic changes over time 
cannot be examined satisfactory by end-point measurements. Therefore, 
a long-term observatory and noninvasive approach could greatly enhance 
the possibilities of gaining new qualitative and quantitative information on 
in vivo Egr-1 gene activation. 
 
1.5 Aim of the thesis 
 
The aim of this thesis was the characterization of the transgenic Egr-1-luc 
murine model. First, it had to be established that this model is working as 
designed and that both proteins, the Egr-1 and luciferase protein products, 
are expressed and transcribed simultaneously without competitively 
inhibiting each other. To exemplary validate the suitability of primary cells 
cultured from Egr-1-luc mice for in vitro monitoring of Egr-1 activity, I 
isolated and cultured smooth muscle cells from aortic tissue to measure 
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Egr-1 promoter activity quantitatively using luciferase luminescence. It 
then had to be validated if this model is suitable for the qualitative and 
quantitative study of Egr-1 expression patterns over time in the living 
animals. To verify this, I applied this model to study Egr-1 promoter 
driven luciferase expression during the development of neonatal mice 
between the ages of 7 - 21 days after birth to observe Egr-1 promoter 
activity over time. I followed the temporal and spatial activation pattern 
of Egr-1 during wound healing and tissue regeneration in a model for 
wound healing of ear tissue and in a model for liver regeneration after 
one-third liver hepatectomy. To confirm the body luminescence imaging 
(BLI) data obtained, I visualized luciferases and Egr-1 activity using 
immunohistochemical analyses in regions of interest in mice embryos as 
well as in the liver tissue of the same animals used prior for BLI prior. I 
carried out additional analyses of the protein and mRNA levels in liver 
tissue, using Western blot and quantitative Real-time Polymerase Chain 
Reaction respectively, to further validate the BLI data of liver 
regeneration. 
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2. Materials and Methods 
	  
2.1 In vivo experiments 
	  
2.1.1 Materials and equipment 
• -20˚C Refrigerator (Bohmann, Kempen) 
• Aqua ad iniectabilia Diaco® (Braun, Melsungen) 
• Carprofen (Pfitzer, Berlin) 
• Disposable Scalpel (Feather, Japan) 
• D-Luciferin (Promega, Hilden) 
• Ear notcher (Napox) (Heiland, Hamburg) 
• Ethanol (Merck, Darmstadt) 
• Ethylene diamine tetra-acetic acid (EDTA) (Biochrom, Berlin) 
• Fentanyl (Janssen-Cilag, Neuss) 
• Formaldehyde (Merck, Darmstadt) 
• Histosette® embedding cassettes (Simport, Canada) 
• Isoflurane (Abbott, Wiesbaden-Delkenheim) 
• IVISTM Lumina Imaging System (Caliper Life Sciences GmbH, 
Mainz) 
• Midazolam (Ratiopharm, Ulm) 
• Medetomidine Dorbene® Vet (Pfitzer, Berlin) 
• Phosphate buffered saline (PBS) (Sigma-Aldrich, Steinheim) 
• Sodium-chloride solution (B. Braun, Melsungen) 
• Surgical instruments (Dumont Medical; FST, USA) 
• Sutures: 
• Ethicon Prolene 4.0 (Johnson & Johnson, USA) 
• Ethicon Sutupak Silk 4.0 (Johnson & Johnson, 
USA) 
• Ethicon Vicryl Sutures 5.0 (Johnson & Johnson, 
USA) 
• Syringes (Braun, Melsungen) 
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• Vaporizer: VIP 3000® Isoflurane (Midmark, USA) 
• XGR-8 Gas Anesthesia System (Caliper Life Sciences GMBH, 
Mainz) 
• Xylazin Rampun® 2 % (Bayer, Leverkusen) 
 
2.1.2 Animals 
	  
The Egr-1-luc transgenic mice of C57BL/6 background were housed in 
individually vented cages with a 12h day/night cycle with chow and water 
provided ad libitum. Male and female mice at different ages were used for 
the experiments. All animals were given adequate care and all animal 
procedures were approved and controlled by the local ethics committee 
and carried out according to the institutional guidelines and in compliance 
with the guidelines of the German law for protection of animal life. 
	  
2.1.3 The Egr-luc murine model 
	  
Transgenic Egr-luc mice were generated previously in our laboratory 
(Vogel 2003). For this purpose, 1200 bp of the murine full-length Egr-1 
promoter sequence was cloned into the plasmid pUHC13-2 replacing the 
CMV promoter in the CMV-Luc expression cassette. The vector containing 
the murine Egr-1 promoter was a generous gift from Martin Braddock 
(Glaxo Wellcome, United Kingdom). From this vector, the Egr-1 promoter 
(Tsai-Morris, Cao et al. 1988) compassing the sequence from -930 to 
+237 base pairs relative to the Egr-1 promoter transcriptional start site 
(Gius, Cao et al. 1990; Schwachtgen, Houston et al. 1998) was isolated 
by SalI restriction. 5' ends were filled-in with DNA polymerase I (Klenow 
enzyme) and cloned into the pUHC13-2 vector by blunt end ligation 
thereby replacing the CMV promoter. The pUHC13-2 vector, which was a 
generous   gift   from  H.  Bujard  (ZMBH,  Germany),  is   a   derivate   of  
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pUHD10-1 (Deuschle, Pepperkok et al. 1989) and was originally 
developed by U. Baron in the laboratory of H. Bujard. In short, the 
reporter plasmid pUHC13-2 containing the promoter-enhancer sequence 
of the CMV promoter followed by a polylinker and the luciferase gene of 
Photinus pyralis (firefly) fused to the SV40 small-t intron and poly(A) 
signal was digested with HindIII and XhoI to excise the CMV promoter. 
The 5'ends were filled in with Klenow enzyme and ends were 
dephosphorylated with alkaline phosphatase. After cloning the Egr-1 
promoter into pUHC13-2 vector, the Egr-1 promoter - luciferase reporter 
gene - SV40 small-t intron fragment was isolated by AseI and PvuI 
digestion. Finally the transgene was purified using a QIAquick Gel 
Extraction Kit (Qiagen). All constructs obtained were reviewed and 
verified by sequencing. Transgenic mice were established by 
microinjecting the plasmid into male pronuclei (identified by size) of 
murine zygotes and transferred into pseudo-pregnant females (strain 
C57BL6). The presence of the transgene was confirmed by means of PCR 
using a specific primer combination spanning the region between the 
reporter gene luciferase and the SV40 small-t intron (forward primer: 5'- 
GAG ATC GTG GAT TAC GTC GC - 3'; reverse primer: 5'- TGC TCC CAT 
TCA TCA GTT CC -3'). For the Egr-1-luciferase construct seven founder 
animals were obtained. Breeding of founder animals with wild-type mice 
(C57Bl6, Harlan) led to an establishment of two lines (L1 and L2) that 
were bred further using exclusively animals that tested positive for 
luciferase expression by luminescence. Egr-1-luc transgenic mice are 
viable and healthy and show a normal life span, indicating no serious 
malformation due to the presence of the transgene. Breeding capabilities 
were also normal with a litter size of 5 - 8 pups, indicating no serious loss 
of function of the Egr 1 gene product. 
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2.1.4 In vivo imaging of luciferase activity  
 
In vivo imaging for bioluminescence was performed using the IVISTM 
Lumina Imaging System (Caliper Life Sciences GmbH, Mainz). The images 
were acquired by a CCD-Camera, thermoelectrically cooled to -90˚Celsius 
for optimal results, in a light-tight imaging chamber and on a movable 
heat-controlled stage. The bioluminescence signal was collected for one to 
three minutes, depending on the bioluminescence intensity. Reflected 
light pictures were taken during illumination with four white LEDs. Image 
acquisition and processing was carried out using Living Image 2.60.1 – 
IGOR Pro 4.09 Software. An illustration of the IVISTM imaging system is 
provided in figure 8. 
 
Figure 8: Illustration of the IVISTM imaging system (Rice, Cable et al. 
2001) 
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For the developmental studies, Egr-1-luc transgenic mice were 
anesthetized by i.p. injection of xylazin/ketamin/luciferin (0.375, 0.635 
and 100 µl D-luciferin in PBS, respectively). For the one-third liver 
hepatectomy model, the animals were anaesthetized by administration of 
isoflurane by a gas manifold with a flow rate of 2.0 % during treatment at 
indicated time points and received 50 µl carprofen and 100 µl D-luciferin 
(60mg/ml D-Luciferin diluted in PBS) by i.p. injection. After 8 – 9 min, the 
animals were killed by cervical dislocation and the body cavity was 
opened immediately thereafter. BLI from the exposed liver were collected 
10 min after luciferin injection. As a control, the exposed livers of sham 
operated animals were measured. 
For the ear wound healing model, the animals were anaesthetized by 
administration of isoflurane and received 100 µl D-luciferin (60mg/ml D-
Luciferin diluted in PBS) by i.p. injection. BLI from the ear region was 
carried out 10 min after luciferin injection. The ear was immobilized with 
adhesive tape during imaging. As a control, the untreated ear was 
measured. 
 
2.1.5 One third liver hepatectomy  
 
Hepatectomy was carried out based on a protocol by Mitchell and 
Willenbring (Mitchell and Willenbring 2008) with slight modifications. Mice 
were anaesthetized by administration of isoflurane and were injected i.p. 
with 50 µl carprofen for pain reduction. All surgical steps were carried out 
as described (Mitchell and Willenbring 2008), except that only the median 
liver lobe was resected. For this, the ventral skin was sterilized by the 
application of 70 % ethanol solution. The liver was exposed by a 2.5 – 3.0 
cm long midline abdominal incision through the skin and muscle tissue 
and made accessible by the use of a rubber band under the xiphoid 
process and special retractors. The organ was pushed down using a saline 
moistened cotton tip and the falciform ligament was cut with 
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microsurgery scissors. The ligament connecting the caudate and left 
lateral lobe was cut in a similar fashion. A 4.0 thread was placed on the 
base of the median lobe above the gall bladder, but at least 2 mm from 
the suprahepatic vena cava, and knotted. The lobe was resected with 
microsurgery scissors directly above the knotted part, only leaving a 
small ischemic stump behind. The peritoneum and skin were sutured 
using 4.0 threads. The mice were allowed to awake at 100 % oxygen flow 
and were carefully evaluated for 20 to 30 minutes. After surgery, mice 
received i.p. injections of 50 µl carprofen daily for pain reduction. In 
control animals, only the midline abdominal incision was performed and 
sutured. At indicated time points after surgery, animals were 
anaesthetized, the liver was exposed by laparotomy and images of the 
ventral view of the fully exposed liver were collected. 
 
2.1.6 Collection of mice embryos 
 
The mother animal was euthanized by an overdose of narcotics 
(Midazolam, Medetomidine, Fentanyl) at the indicated developmental 
stage of the embryos and the uterus was surgically exposed by midline 
abdominal incision and opened. The mice embryos were collected in 
embedding cassettes (Histosette) and stored over night in formaldehyde 
solution. The embryos were then transferred into EDTA solution and 
stored for 2 weeks until further processing. 
 
2.1.7 Ear wound healing model  
 
A punch wound of approximately 1.5 mm in diameter was inflicted with 
an ear notcher on one ear of Egr-1-luc animals according to the standard 
procedure of animal labeling. 24 h after the wound setting, BLI from the 
ear region was carried out. As a control, the untreated ear was measured. 
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2.2 In vitro experiments 
 
2.2.1 Materials and equipment 
• -80˚C Refrigerator: Herafreeze® (Thermo Scientific, USA) 
• -20˚C Refrigerator (Liebherr, Biberach an der Riss) 
• 4˚C Refrigerator (Liebherr, Biberach an der Riss) 
• 12 well culture cluster (Corning incorporated, USA) 
• 24 well culture cluster (Corning incorporated, USA) 
• Acetic acid (Merck, Darmstadt) 
• AequoriaMDSTM Macroscopic Imaging System (Hamamatsu, 
Herrsching am Ammersee) 
• Amphotericin B (Sigma-Aldrich, Steinheim) 
• ATP (Roche, Mannheim) 
• BCA Proteinassay Kit (Pierce; Thermo Scientific, IL, USA) 
• Camera: Hamamatsu 1394 ORCA-ERA (Hamamatsu, Herrsching am 
Ammersee) 
• cDNA Synthesis Kit for RT-PCR (Roche, Mannheim) 
• Cell Culture dishes (TPP, Switzerland) 
• Cell lysis solution (Promega, Mannheim) 
• Centrifuge 5424 (Eppendorf, Weseling) 
• Centrifuge Micro 200R (Hettich, Tuttlingen) 
• Chloroform/isoamylalcohol (49:1) (Fluka, Deisenhofen) 
• CoA (Sigma-Aldrich, Steinheim) 
• Collagenase II (Sigma-Aldrich, Steinheim) 
• Disposable scalpel (Feather, Japan) 
• D-luciferin (Promega, Mannheim) 
• Dry milk (Merck, Darmstadt) 
• DTT 1,4-dithiothreitol (Sigma-Aldrich, Steinheim) 
• Ethylene diamine tetra-acetic acid (EDTA) (Biochrom, Berlin) 
• Ethylene glycol-bis tetra-acetic acid (EGTA) (Sigma, Munich) 
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• Ethanol (70%, 96%, 100%) (Merck, Darmstadt) 
• Fetal Calf Serum (10 %) (Gibco, Darmstadt) 
• Gelatin (Merck, Darmstadt) 
• Gel blot paper (Whatman, Great Britain) 
• GelCode blue staining reagent (Pierce; Thermo Scientific, USA) 
• Glutamine (Biochrom, Berlin) 
• Glycerol (Merck, Darmstadt) 
• Gradient-gel (Serva, Heidelberg) 
• Guanidine (Sigma, Munich) 
• Guanidine Thiocyanate (Sigma, Munich) 
• HAM’s F12 medium (Biochrom, Berlin) 
• Hydrogen Peroxide (Merck, Darmstadt) 
• Horseradish peroxidase (HRP) conjugated rabbit polyclonal antibody 
against firefly luciferase (1:1000) (Santa Cruz Biotechnology, USA) 
• Incubator CB53 (Binder, Tuttlingen) 
• Isopropanol (Sigma, Munich)  
• Potassium chloride (Merck, Darmstadt) 
• Laemmli-buffer 10x (Serva, Heidelberg) 
• Lithium Chloride (Sigma, Munich) 
• Light Cycler 1.5 (Roche, Mannheim) 
• Light Cycler® FastStart DNA MasterPlus SYBR Green I Kit (Roche, 
Mannheim) 
• M199 Medium (Biochrom, Berlin) 
• MaXtract High Density containers (Quiagen, USA) 
• Mercaptoethanole (Sigma, Munich) 
• Methanol (Merck, Darmstadt) 
• Magnesiumchloride (Merck, Darmstadt) 
• Microscope (Zeiss, Oberkochen) 
• Microtome model MED Hn40 (Leica Microsystems, Bensheim) 
• Sodium fluoride (Sigma, Munich) 
• Nitro-cellulose-membrane (Pierce; Thermo Scientific, USA) 
• N-Lauroylsarcosine sod. Salt (Sigma, Munich) 
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• Non-fat dry milk (Bio-Rad Laboratories, Munich) 
• Nonamers (Roche, Mannheim) 
• Ponceau Sodium Salt (Santa Cruz Biotechnology, Inc., USA) 
• Penicillin 10000 IE (Biochrom, Berlin) 
• Phenol (Sigma, Munich)  
• Phenylmethylsulfonyl fluoride (PMSF) (Boehringer, Ingelheim am 
Rhein) 
• Phosphate buffered saline (PBS) (Sigma-Aldrich, Steinheim) 
• Photometer: BioPhotometer (Eppendorf, Weseling) 
• Pipettes 10,20,100,200,1000µl (Eppendorf, Weseling) 
• Poncau-S-color solution (Sigma, Munich) 
• Potassium-chloride (Merck, Darmstadt) 
• Rabbit monoclonal antibody against Egr-1 (1:500) (Cell Signalling, 
USA) 
• Rabbit monoclonal antibody against β-actin (1:2000) (Sigma, 
Munich) 
• Recombinant luciferase (Promega, Mannheim)  
• Restore western blot stripping buffer (Pierce; Thermo Scientific, 
USA) 
• RQ1 RNase-free DNase (Promega, USA) 
• Scale: RET Basic (IKA Labortechnik, Staufen) 
• Sodium-acetate (anhydrous) (Sigma, Munich) 
• Sodium bicarbonate (Gibco, Darmstadt) 
• Sodium citrate tribasic dihydrate (Sigma, Munich) 
• Sodium orthovanadate (Sigma, Munich) 
• Sonicator: Ultrasonic Processor XL® (Heat Systems, USA) 
• Streptomycin (Biochrom, Berlin) 
• Sucrose (Sigma, Munich) 
• Super Signal West Femto Maxim 1 kit (Pierce; Thermo Scientific, 
USA) 
• Surgical micro scissors (Dumont Medical; FST, USA) 
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• Tris buffered saline buffer 10x: 24.2g Tris base (Applichem, 
Darmstadt), 80 g NaCl (Applichem, Darmstadt), 165 ml 1M HCl 
(Merck, Darmstadt), 835 ml distilled water 
• Thiocyanate (Sigma, Munich) 
• Tris-glycine gel (4–20%) (Serva, Heidelberg) 
• Tris-Hydrochloric acid: 1M Tris buffer (Applichem, Darmstadt) and 
HCl (Merck, Darmstadt) 
• Triton X-100 (Sigma-Aldrich, Steinheim) 
• Trypsin (Biochrom, Berlin) 
• Tube luminometer (Lumat LB 9507, Berhold Technologies, Bad 
Wildbad). 
• Tween (0.1%) (New England Biolabs, USA) 
• Waterbath (GFL, Burgwedel) 
• Waymouth (Gibco, Darmstadt) 
• Xylol (Merck, Darmstadt) 
	  
2.2.2 Cell culture 
 
Primary cultures of murine aortic smooth muscle cells (SMC) were 
established as previously described (Pelisek, Armeanu et al. 2001). Male 
and female mice were killed by an overdose of narcotics (midazolam, 
medetomidine, fentanyl) and the ascending and descending aorta was 
removed. Fat and surrounding tissues were removed with a disposable 
scalpel under a microscope (Zeiss, Oberkochen) and the aorta was cut 
lengthwise with micro scissors. The tissue pieces were incubated with a 
small amount of enzyme solution (0.1 % collagenase II, 0.1 % trypsin 
diluted in PBS) for 20 min at 27˚C. The solution was exchanged with a 
small amount of M199 medium and the endothelial cells were detached 
and removed by gently scraping the surface and pipetting the solution up 
and down several times. The aortic tissue was cut into small sections and 
the tissue pieces were placed on gelatin coated plates and covered with 1 
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ml of culturing solution after adhesion (standard HAM’s F12/Waymouth 
1:1 medium, 10 % FCS (fetal calf serum), 4 mM glutamine, 100 U 
penicillin, 100 µg/ml streptomycin, 2.5 mg/ml amphotericin B) for 
outgrowth of SMC’s. The medium was exchange every 24 to 36 hours. 
After the SMC’s were growing out, the tissue pieces were removed and 
the cells were split. The cells were seeded into gelatin coated twelve-well 
plates with the same medium for culturing. Cells were cultured at 37˚C in 
a 5 % CO2 humidified atmosphere. For stimulation, cells between 
passages three and four were serum starved for two days. 
 
2.2.3 Luciferase assay 
	  
Smooth muscle cells were harvested at a confluence of 70 – 90 % by 
trypsination, collected by centrifugation for 10 min at 1000 rpm and lysed 
for 20 to 30 min in 0.5x lysis buffer solution at room temperature. 
Quantification of luciferase activity was performed in cell lysates as 
described (Ogris, Carlisle et al. 2001). For quantification, an aliquot of cell 
lysate was quantified using a tube luminometer (Lumat LB 9507, Berhold 
Technologies, Bad Wildbad). Measurements were taken with an 
integration time of 10 sec, following a lag time of 2 sec after the injection 
of the luciferases assay reagent (LAR; 20mM glycylglycine, 0.1 mM EDTA, 
3mM DTT, 0.55 mM ATP, 0.3 mM CoA, 0.5 mM D-luciferin, pH 8.5). As 
control of the background auto-florescence level, the values of wild-type 
cells were measured and deducted from the measurement; two ng 
recombinant luciferase (Promega) correspond to 107 relative light units 
(RLU). 
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2.2.4 RNA isolation 
 
Total RNA was isolated based on a protocol by Chromzynski and Sacchi 
(Chomczynski and Sacchi 1987) with slight modifications from frozen liver 
samples 12 h after hepatectomy or sham operation (n=4). For RNA 
extraction, 30 mg tissue specimen were mechanically homogenized with 
600 µl denaturing solution, containing 4 M guanidinium thiocyanate, 25 
mM sodium citrate, pH 7.0, 0.5 % (wt/vol) Nlaurosylsarcosine (sarkosyl) 
and 0.1 M 2-mercaptoethanol. The denaturing solution was prepared by 
dissolving 367,6 mg 25 mM sodium citrate tribasic dehydrate, pH 7, in 50 
ml distilled water, adding 23,6 g 4 M guanidine thiocyanate, 0.25 g 0.5 % 
N-lauroylsarcosine sodium salt/50 ml and 50 ml 0.1 M 2-mercaptoethanol. 
A 2 M sodium acetate solution was prepared by adding 16.42 g anhydrous 
sodium acetate to 40 ml water and 35 ml glacial acetic acid pH 4 (glacial 
acetic acid brought to a final volume of 100 ml with water) for the next 
step. After transfer of the tissue into a polypropylene tube, 60 µl 2 M 
sodium acetate solution, pH 4, 600 µl water-saturated phenol and 120 µl 
chloroform/isoamylethanol (49:1) were added sequentially, shaking the 
mixture for 1 min after addition of each ingredient to ensure thorough 
mixing of the organic and acidic-aqueous phase. The entire volume was 
transferred into 2 ml MaXtract high-density containers, cooled for 15 min 
on ice and centrifuged for 2 min and 12000 rpm at 4˚C. The upper 
aqueous phase was transferred into a 1.5 ml tube and 1 µl glycogen and 
600 µl isopropanol were added to precipitate the RNA. After storage over 
night at -20˚C, the pellet was collected by centrifugation for 30 min and 
12000 rpm, re-suspended in 1 ml 70 % ethanol to wash the RNA and 
recovered by centrifugation for 5 min. and 12000 rmp. The pellet was re-
suspended in 90 µl denaturing solution (as described above), 90 µl 
isopropanol were added to precipitate the RNA and the mixture was 
stored for 1 hour or over night at -20˚C. The pellet containing the 
isolated RNA was collected by centrifugation for 20 min and 12000g and 
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was re-suspended in 48 µl water. The isolated total RNA was incubated at 
37C˚ for 30 min after the addition of 6 µl 10x TBS buffer and 6 µl DNAse 
(RQ1 RNase-free DNase 1000 U, 1U/µl). The reaction was stopped by the 
addition of 140 µl water and incubation for 10 min at 65˚C. 100 µl phenol 
and 100 µl chloroform/isoamylalcohol (49:1) were added, the volume was 
transferred into 2 ml MaXtract high density containers, cooled on ice for 
15 min and centrifuged for 2 min and 1200g at 4˚C). The supernatant 
was transferred into a 1.5 ml tube, 300 µl isopropanol and 30 µl 4 M 
Lithium-Chloride were added to precipitate the RNA and the mixture was 
stored for 1 hour at -20˚C. The pellet was collected by centrifugation for 
15 min and 13000 rpm at 4˚C, washed twice using 1 ml 70 % ethanol (as 
described above) and allowed to dry for 10 min at room temperature. For 
further processing, the dry pellet was re-suspended in 100 µl water and 
incubated for 15 min at 64˚C to ensure complete solubilization. To 
measure the concentration of the total RNA in the sample and to estimate 
purity, spectrophotometric readings at wavelength of 260 nm and 280 nm 
were obtained using a photometer (BioPhotometer, Eppendorf). 
 
2.2.5 Quantitative real time Polymerase Chain Reaction (qRT-PCR) 
 
One microgram of DNAse treated total RNA was reverse transcribed using 
random nonamers (Roche, Mannheim) and a 1st Strand cDNA Synthesis 
Kit for RT-PCR (Roche, Mannheim). qRT-PCR was performed with a Light 
Cycler 1.5 (Roche, Mannheim) in a reaction volume of 10µl using a Light 
Cycler® FastStart DNA MasterPlus SYBR Green I Kit (Roche, Mannheim) 
and 50 pmol of each primer (Egr-1, forward: 5´- CGA ACA ACC CTA TGA 
GCA CCT G – 3´; reverse: 5´- CAG AGG AAG ACG ATG AAG CAG C – 3´; 
luciferase, forward: 5´- CAG ATG CAC ATA TCG AGG TG – 3´; reverse: 
5´- CAT ACT GTT GAG CAA TTC ACG – 3´; 18s  rRNA, forward: 5´- GGA 
CAG GAT TGA CAG ATT GAT AG – 3´; reverse: 5´- CTC GTT CGT TAT 
CGG AAT TAA C – 3´). Three independent qRT-PCR reactions were 
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performed on each template. An initial denaturation step at 95°C for 10 
min was followed by 40 cycles of denaturation (95°C, 10 sec), annealing 
(64°C for Egr-1; 58°C for luciferase, 64°C for 18S rRNA, 5 sec), and 
extension (72°C, 15 sec). Melt curve analyses were performed to control 
specific amplification. Results were normalized to the expression levels of 
the 18S rRNA. 
 
2.2.6 Western blot  
 
Total and nuclear protein extracts of liver tissue samples were isolated 48 
h after hepatectomy as described (Barancik, Htun et al. 2000). The liver 
tissue samples were unfrozen and mechanically homogenized in 3 ml ice-
cold buffer solution, containing 0.1 mM sodium orthovanadate, 1 mM 
Phenylmethylsulfonyl fluoride (PMSF), pH 7.4, 1 mM dithiothreitol (DTT), 
1 mM EDTA, 1 mM EGTA, 10 mM potassium-chloride, 50 mM tris-
hydrocloric acid and 250 mM sucrose. 1 ml of the homogenate was 
centrifuged for 10 min and 4000 rpm at 4˚C and the supernatant was 
collected. The supernatant after this step contained the soluble cytosolic 
protein fraction. The pellet was re-suspended in a buffer containing 0.5 
mM PMSF, pH 7.4, 1 mM EGTA, 1 mM DTT, 1 mM EDTA, 10 mM 
potassium-chloride, 10 mM NaF, 50 mM tris-HCl and 1000 mM sucrose 
and homogenized on ice using a sonicator (Ultrasonic Processor XL, Heat 
Systems). The mixture was centrifuged for 30 min and 13000 rpm at 4°C 
and the recovered pellet was re-suspended in a buffer containing 0.1 mM 
sodium orthovanadate, 0.1 % Triton X-100, 0.5 mM PMSF, 1.0 mM DTT, 
1.0 mM EGTA, 10 % glycerol, 50 mM Tris-HCl and 400 mM KCl. The 
mixture was mechanically homogenized on ice to yield the nuclear protein 
fraction. 4x laemmli buffer (10x laemmli buffer containing 0.25 M Tris, 
1.92 M Glycine and 1 % SDS in aqueous solution) was added, the 
proteins were heat-denatured for 5 min at 95˚C, cooled on ice and 
centrifuged at 13000 rpm for 1 min to prepare the probe for western blot 
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analysis. Equal amounts of protein were separated on a 4–20 % Tris-
glycine gel at a voltage of 10 mA/gel for 10 min, followed by 25 mA/gel 
for 70-90 minutes. 1x laemmli buffer was used as electrophoresis buffer. 
After electrophoresis, the buffer was removed and the gel cassette taken 
out. The gel was exposed, equilibrated together with Whatman gel blot 
paper and the nitrocellulose membrane for 5 min in transfer buffer (Tris-
base, glycine, SDS, methanol, water) and assembled from anode to 
cathode. A voltage of 104 mA was applied for 1 hour to transfer the 
protein from the gel to the nitrocellulose membrane. After transfer, the 
membrane was dyed with Ponceau-S solution and washed using a 
washing buffer solution (PBS – Tween (0.1 %)), until bands became 
visible. After documentation, the washing process was continued until the 
bands disappeared and the membrane was blocked with 5 % dry milk in 
washing buffer (as described above). The membrane was washed with 
TBS washing buffer three times for 10 min respectively. Immunoreactive 
bands were visualized using Super-Signal-Femto-West (Pierce) with a 
HRP conjugated rabbit polyclonal antibody against firefly luciferase 
(1:1000, Santa Cruz Biotechnology), a rabbit monoclonal antibody against 
Egr-1 (1:500, Cell Signaling) or β-actin (1:2000, Sigma), respectively. 
Luminescence was evaluated using Hamamatsu 1394 ORCA-ERA camera, 
AequoriaMDSTM Macroscopic Imaging System and Wasabi software 
(Hamamatsu Photonics, Herrsching, Germany). Protein bands were 
quantified by densitometry, and results expressed as Luc/ß-actin and Egr-
1/ß-actin ratio, respectively. For negative control, the first antibody was 
omitted. Blots were repeated at least twice. 
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2.3 Immunohistochemistry 
	  
2.3.1 Materials and equipment 
	  
• 4˚C Refrigerator (Liebherr, Biberach an der Riss)	  
• Aminoethyl carbazole (AEC) single solution, (Invitrogen, USA)	  
• Anti-luciferase goat polyclonal horseradish peroxidase (HRP) 
conjugated antibody (1:50) (Abcam, United Kingdom)	  
• Camera: AxioCam HRm (Zeiss, Oberkochen)	  
• Citrate-buffer: 5,882 g Tri-Sodium-Citrate (Merck, Darmstadt) in 
2000 ml distilled water, buffered with 6 mol HCl solution to pH 6	  
• Embedding cassettes Histosette (Simport, Canada)  
• Embedding-machine: Shandon Citadel 1000 (Thermo Fisher 
Scientific, USA) 
• Ethanol (70%, 96%, 100%) (Merck, Darmstadt)  
• Haemalaun stain (Roth, Karlsruhe) 
• Histosette (Simport, Canada) 
• Hotplate (Severin, Sundern) 
• Hydrogen peroxide (Merck, Darmstadt) 
• Luciferase goat polyclonal horseradish peroxidase (HRP) conjugated 
antibody (1:50) (Abcam, United Kingdom) 
• Methanol (Merck, Darmstadt)	  
• Microscope Axiovert 200 (Zeiss, Oberkochen) 
• Microtome model MED Hn40 (Reichert-Jung, Bensheim) 
• Paraffin wax Paraplast plus (Sigma-Aldrich, USA) 
• Paraformaldehyde (PFA, 4%)(Merck, Darmstadt)	  
• Phosphate buffered saline (PBS) (Merck, Darmstadt)	  
• Pipettes 10,20,100,200,1000µl (Eppendorf, Weseling) 
• Pronase E (Merck, Darmstadt)  
• Sakura® Tissue TEC® TECTM (Sakura, Leiden) 
• Scale: RET Basic (IKA Labortechnik, Staufen) 
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• Shandon cover plates (Thermo Scientific, USA) 
• SuperFrostTM Slides (Thermo Fisher Scientific, USA) 
• Tris-buffer: 60,58g Trisma base (Sigma, Munich) solved in 400ml 
distilled water, buffered with N HCl solution to pH 7.5 and diluted to 
1000 ml with distilled water 
• Tween 20 (Sigma-Aldrich, USA) 
• Water bath (GFL, Burgwedel) 
• Ultramount (Dako, Hamburg) 
• Vectastain Elite ABC Kit (Rabbit IgG) (Vektor, CA, USA) 
• Xylene (Roth, Karlsruhe) 
 
2.3.2 Formalin fixation and paraffin embedding 
	  
For immunhistochemical detection of luciferase and Egr-1, the harvested 
liver tissue was fixed in 4 % paraformaldehyde (PFA) over night at 4°C 
and subsequently embedded in paraffin. Embryos (n = 6, littermates) 
were collected at day 14 of development for detection of luciferase and 
Egr-1.	   They were transferred into embedding cassettes (Histosette) 
immediately after removal and stored in 4 % PFA solution for 24 to 48 h 
for fixation. They were placed in a solution of Na4EDTA 
(ethylenediaminetetraacetic acid tetrasodium salt), 200 g/L, pH 7.1 
(adjusted using 20 % w/v citric acid) at room temperature for 14 days to 
ensure decalcification. The embryos and the liver tissue were rinsed for 1 
hour with running water and stored in 70 % ethanol until further 
processing. The embedding-machine (Shandon Citadel 1000, Thermo 
Scientific) was prepared by filling the respective tanks with 70 % ethanol, 
96 % ethanol, xylene and paraffin wax Paraplast Plus. The samples were 
automatically dehydrated and embedded in paraffin wax by bathing them 
in a graded alcohol series (twice (2 hours and 1 hour) in 70 % ethanol, 
once (1.5 hours) in 80 % ethanol, once (1.5 hours) in 90 % ethanol, 
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twice (1.5 and 1 hours) in 96 % ethanol, twice (1.5 and 1 hour) in pure 
alcohol) bathing them twice (1.5 and 1 hour) in xylene and twice in 60˚C 
warm paraffin wax (Paraplast Plus). The tissues were then stored 60˚C 
warm paraffin wax until embedment into a paraffin block using the 
Sakura® Tissue TEC® TECTM system. 
After cooling down to room temperature, the embedded tissues were cut 
into 4 µm thick sections, flattened in a 40˚C warm water bath and 
mounted on the specimen slides (SuperFrostTM microscope slides). The 
specimen slides were allowed to dry overnight at 37˚C before staining. 
	  
2.3.3 Egr-1 dyeing 
	  
The dried specimen slides were de-pariffinized twice for 15 min in xylene, 
rehydrated in a graded alcohol series (5 min each in pure ethanol, 96% 
ethanol and 70 % ethanol) and rinsed for a short time with distilled water. 
Egr-1 antigen retrieval was performed in a steamer with sodium citrate 
buffer (5,882 g tri-sodium-citrate in 2000 ml distilled water), pH 6.0 – 
adjusted using 6 mol HCl solution) for 20 min and rinsed for 5 min with 
PBS/Tween. Endogenous peroxidase activity was quenched by treatment 
with 3 % hydrogenperoxide (3 ml H2O2, 180 ml methanol) for 5 minutes 
before being transferred on Shandon cover plates. For Egr-1 staining, 
slides were incubated over night at 4˚C with a rabbit anti-mouse antibody 
(1:50 in PBS/Tween). Slides were rinsed with PBS/Tween (3 min) and 
incubated with a secondary antibody from the rabbit ABC kit 
(VECTASTAIN® Elite ABC system, Vector) according to the manufacturer’s 
instructions. Immunoreactivity was visualized with the chromogen 3-
amino-9-ethyl-carbazole (AEC single solution) for 20 min. As negative 
control the primary antibody was omitted.	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2.3.4 Luc dyeing 
	  
The dried specimen slides were de-pariffinized as described above. 
Antigen retrieval for luciferase staining was achieved with Pronase E 
diluted in 0.5 M Tris buffer (1mg Pronase E in 1 ml Tris-buffer) for 15 min 
at room temperature and rinsed for 5 min with PBS/Tween (0.1%). 
Peroxidise blockage was performed as described above before the 
samples were mounted on Shandon coverplates. 
Slides were incubated over night at 4°C with a polyclonal goat-anti-
luciferase horseradish peroxidase (HRP) conjugated antibody (Abcam, 
1:50 in Tris-buffered saline (TBS). Immunoreactivity was visualized with 
the chromogen 3-amino-9-ethyl-carbazole solution (AEC single solution) 
for 20 minutes and rinsed in PBS/Tween. The tissue was counterstained 
with haemalaun (10 sec) to visualize the cell nuclei, rinsed in water and 
sealed with Ultramount. 
Pictures were taken on a Zeiss Axiovert 200 microscope with a Zeiss 
AxioCam HRm camera, using 20x objective (Zeiss) and 4x/10x lenses 
(Zeiss). 
 
2.4 Software 
	  
• Adobe Photoshop CS 3 
• Living Image 2.60.1 – IGOR Pro 4.09 Software  
• Microsoft Office Word 2007 
• Microsoft Office Excel 2007 
• Wasabi software (Hamamatsu Photonics, Herrsching, Germany) 
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2.5 Statistics 
 
All statistical analyses were performed using WinStat. p-values <0.05 
were regarded as statistical significant and calculated using either the 
non-parametric U-test (according to Mann-Whitney) or the Wilcoxon test. 
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3 Results 
	  
3.1 Cell culture  
 
Vascular smooth muscle cells (SMC) isolated form aortic tissue of adult 
Egr-1-luc mice were cultured in vitro and the luciferase activity measured 
in cell lysates to analyze exemplary, whether or not primary cells from 
Egr-luc mice might also be suitable for in-vitro investigations. On average, 
4,000 RLU were measured per well (12-well plate, background value of 
luc-negative cells >300 RLU/well). 
 
3.2 The Egr-luc murine model 
 
Transgenic Egr-1 - luc mice were generated previously in our laboratory 
(Vogel 2003). To show functional expression of luciferase, adult Egr-1-luc 
mice were injected with the luciferase substrate D-luciferin and the 
activity monitored by BLI in anaesthetized animals. A representative 
image is shown in figure 9. 
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Figure 9: Luciferase activity in adult Egr1-luc mouse 
Transgenic Egr1-luc mice (16 weeks old, male or female) were 
anaesthetized by administration of isoflurane and received 6 mg 
luciferin in 100 µl PBS by i.p. injection. 10 min after injection BLI 
measurement was carried out (1 min signal collection, setting ‘high 
resolution’). A representative animal is shown. The reflected light 
picture is overlaid by a color-coded BLI image visualized in ‘blend 
mode’, which allows allocating the BLI signal to the respective areas 
shown in the underlying reflected light picture. 
 
In the living animal, highest signal intensities were observed in regions 
around the snout (especially lips), ears and paws, whereas luciferase 
signal in other regions was not detectable. The absence of signal 
detection in fur-covered regions could partly be due to quenching effects. 
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3.3 In vivo monitoring of Egr-1 promoter activity during 
postnatal development and embryogenesis  
 
To monitor expression of the reporter during postnatal development, Egr-
1-luc transgenic mice were imaged at 7, 10, 13, 16, 19 and 21 days after 
birth. Day 7 was the earliest possible date for the i.p injection of the 
anesthetic and luciferase. Animals from the same litter were measured for 
luciferase activity on indicated dates and were kept with the parent 
between the measurements to ensure feeding by lactating mother 
animals. For luciferase signal quantification we used defined regions of 
interest (ROI), which were placed over the snout and paw of the mice. 
Due to the lack of hair growth, which otherwise could reduce the 
luciferase signal and interfere with signal quantification, we did not expect 
significant signal quenching. The total number of photons collected per 
area was normalized to background levels by subtraction of the total 
counts per area measured in an equal sized ROI placed over a 
background area of the same picture. As shown in figure 10A, mice 
showed strong luciferase expression throughout the entire ventral side of 
the body at day 7 after birth. A clear reduction of overall luciferase 
activity, including paws, snout, ears and tail, was observed during their 
development throughout the next 2 weeks. When quantifying the 
luciferase signal in ROI’s at paw (Fig 10B) and snout (Fig 10C), luciferase 
activity was found to be reduced over time reaching 30 or 40 %, 
respectively, at day 21 compared to the initial value at day 7. 
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Figure 10: Egr-1 promoter driven luciferase activity during 
postnatal development (day 7 - 21 after birth) 
Luciferase activity in Egr-1-Luc mice at indicated age (days after birth) 
was measured by bioluminescence imaging (BLI) after i.p. injection of D-
luciferin. Luciferase signal was collected for 10 sec from the ventral side 
of the mice. (n=6) 
A: A reflected light picture of representative animals at indicated age is 
overlaid by a color-coded BLI image. The numbers on the upper left 
indicate the age in days after birth. B and C: Luciferase activity was 
quantified within regions of interest (ROI’s) placed at the paw (B) or 
snout area (C) and expressed as photons per second per cm2 to correct 
for size differences in ROI size at different ages. A background ROI of 
equal size was subtracted. Median values of six animals + standard 
deviation are shown. * p < 0.05, *** p < 0.001; indicated day vs. day 7, 
Wilcoxon test. 
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3.4 Embryonic development: immunohistochemical analyses 
 
I evaluated Egr-1 promoter activity in transgenic and non-transgenic 
embryos on day E14 of development (Theiler Stage 22) by 
immunohistochemical analyses of luciferase (Fig 11). In accordance with 
the BLI data obtained from the Egr-1-luc transgenic mice, bone primordia 
of hind limbs stained positive for luciferase (Fig 11A). Various neuronal 
structures demonstrated luciferase activity but it was mainly located at 
the sympathetic paravertebral ganglia (Fig 11B). Furthermore, an intense 
immunoreactivity was detected at the masticatory apparatus, especially 
at the area of the palatal shell (Fig 11C); snout and whisker follicles 
showed only slight staining (data not shown). The tissue specimens of 
non-transgenic control animals did not display any positive staining for 
luciferase (Fig 11D-F). When staining sections with anti Egr-1 antibody, a 
comparable pattern to luciferase staining could be observed, as for 
example at the masticatory apparatus (Fig 11G). 
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Figure 11: Immunohistochemical analyses of luciferase and Egr-1 
expression during embryonic development 
Egr-1-luc (A, B, C and G) and wild type (D, E and F) C57BL/6 embryos on 
day E14 of development were stained for luciferase protein (A-F) or Egr-1 
protein (G). In bone primordia of hindlimbs (A, D), sympathetic 
paravertebral ganglia (B, E) and masticatory apparatus (C, F) luciferase 
positive areas (arrows) are stained in lilac in transgenic embryos (A-C), in 
wild-type embryos no luciferase signal is detected (D-F). When staining 
for Egr-1 protein, a similar pattern of protein expression is found in the 
masticatory apparatus (G) as for luciferase (C); scale bar: 50 µm 
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3.5 Hepatectomy 
	  
3.5.1 Egr-1 activation in regenerating liver 
 
Liver hepatectomy in rodents leads to induction of cell division in the 
majority of hepatocytes 1-2 days after surgery (Fausto, Campbell et al. 
2006). Here, I used in vivo BLI to verify at first that Egr-1 promoter 
activity can be monitored within the opened abdominal cavity of the Egr-
1-luc transgenic mice and to show that no Egr-1 promoter activity was 
detectable in the untreated liver tissue of 1 month old mice, as shown in 
figure 12. 
 
Fig. 12: BLI of adult Egr-1-luc mice with opened body cavity.  
Transgenic Egr-1-luc mice (one month old) received 6 mg luciferin in 100 
µl PBS by i.p. injection. After 10 min, the animal was killed by cervical 
dislocation, the body cavity opened immediately, skin from the ventral 
side partially removed and BLI measurement was carried out (10 min 
signal collection, setting 'high resolution'). A representative animal is 
shown. 
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I then used the same method to monitor the activity of the Egr-1 
promoter in the transgenic mice 48 h (n=6 and n=3 control) and 72 h 
(n=4 and n=3 control) following one-third hepatectomy. For 
quantification purposes, ROI’s were placed over the areas of regenerating 
liver tissue close to the primary excision site. The highest Egr-1 activity 
was observed at regions directly adjacent to the original sectioning wound 
with some elevated activity at the edges of the liver lobes, as shown in 
figure 13A. 
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Figure 13: Egr-1 promoter driven luciferase activity after partial 
liver hepatectomy 
A: BLI of hepatectomized (left) or sham operated (right) Egr-1-luc mice 
at 48 h (top row) and 72 h (bottom row) after surgery; representative 
animals from n = 3 - 6 are shown. Red arrows denote the site of initial 
surgery, arrowhead points at the edge of a liver lobe showing luciferase 
activity. 
B: Quantitative luciferase signals from ROI’s placed over the liver area of 
sham operated or hepatectomized animals 48 h and 72 h after surgery. A 
representative background ROI of equal size was subtracted to account 
for background activity. n = 3 - 6; * p<0.05 sham vs. hepatectomy (U-
test, Mann-Whitney) 
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When quantifying the BLI signal in the area next to the excision site, an 
up to 12-fold signal increase was observed compared to sham operated 
animals, both at 48 h and 72 h after surgery (Fig 13B). Clusters of cells 
stained positive for Egr-1 (Fig 14A) and for luciferase (Fig 14B) were 
observed in section of liver tissue at the site of surgery after 
hepatectomy. 
 
 
Figure 14: Immunohistochemical analyses of Egr-1 driven 
luciferase expression in regenerating liver 
Egr1-luc mice 4 – 8 weeks of age were subject to one-third liver 
hepatectomy as described. 48 h after surgery mice were sacrificed, liver 
tissue fixed in paraformaldehyde and stained for luciferase. Tissue next to 
the site of surgery (rim lower left corner in both images) is shown and 
cells staining positive for Egr-1 (A) as well as luciferase (B) appear as 
clusters with lilac staining (arrows; scale bar: 50 µm). 
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3.5.2 Quantitative Egr-1 levels in liver regeneration 
 
To obtain a quantitative view on Egr-1 levels in liver regeneration, 
animals were sacrificed 12 h or 48 h after surgery and liver tissue 
homogenized for mRNA and protein quantification of Egr-1 and luciferase, 
respectively (Fig 15). 12 h after surgery, protein levels of Egr-1 were six 
times higher compared to the sham operated group (Fig 15B). For 
luciferase, the mRNA level was not detectable in the sham operated 
group, whereas in hepatectomized animals a strong signal was found. 
Analyzing protein levels 48 h after surgery, an increased signal was found 
for both Egr-1 and luciferase (Fig 15A). Compared to Egr-1 this increase 
was considerably more pronounced for luciferase (Fig 15), which can be 
explained by the fact that luciferase protein has a considerably longer 
intracellular half life of 3 hours, (Thompson, Hayes et al. 1991) than the 
Egr-1 protein, which is degraded more rapidly and has a half live of less 
than 2 hours, generally between 30 min to 1 hour (Waters, Hancock et al. 
1990). 
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Figure 15: mRNA and protein levels of Egr-1 and luciferase after 
partial hepatectomy 
Egr-1-Luc mice were subject to one third hepatectomy or sham operation, 
sacrificed 48h (A) or 12h (B) after surgery and liver tissue subject to 
mRNA analyses by qRT-PCR (B) or Western blotting analyzing protein 
levels of Egr-1 and luciferase (A).  
(A) Representative Western blots showing the protein levels of Egr-1, 
luciferase and β-actin to confirm equal loading for hepatectomized (right 
panel) or sham operated animals (left panel), respectively; data from two 
representative animals per treatment are shown. 
(B) mRNA levels of Egr-1 and luciferase, respectively (average relative 
mRNA levels relative to 18S rRNA levels); mRNA levels of luciferase in 
sham operated animals was below the detection limit. n=4; * p<0.05 
sham vs. hepatectomy (U-test, Mann-Whitney) 
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3.6 Egr-1 activation in wound healing 
 
Using in vivo BLI, I monitored the activity of the Egr-1 promoter in Egr-1-
luc mice immediately after the infliction of a punch wound on the right 
ear. For quantification we used defined ROI’s. The Egr-1 activity showed a 
major increase in the immediate vicinity of the wound, while more distant 
areas did not show any difference compared to the control (Fig 16A). 
Placing a ROI over the area surrounding the wound, a >12-fold increased 
BLI signal was found 24 h after infliction of the wound when compared to 
an equal sized ROI on the adjacent control ear (Fig 16B). 
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Figure 16: In vivo bioluminescence imaging of the ear-wound 
In Egr-1-luc mice between the ages of 4 – 8 weeks an ear wound was 
inflicted in one ear. 0 h and 24 h after infliction animals were subject to 
BLI. Luciferase signal was collected for 2 min from the wounded ear or 
the control ear.  
(A) Color coded BLI image overlaid onto a reflected light image from the 
control ear (left) or wounded ear (right) immediately (top row) or 24 h 
(bottom row) after wound infliction. 
(B) Quantitative luciferase signals from ROI’s placed over the wound site 
or an equal sized ROI at the control ear immediately after the wound 
infliction (before) and 24 h thereafter (after); n=3; * p<0.05 control vs. 
wound (U-test, Mann-Whitney) 
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4 Discussion 
 
The data collected in this study on both, Egr-1 and luciferase, is in line 
with previously published data on Egr-1. Data of all end-point and in vitro 
studies are in accordance with in vivo data and studies about protein 
kinetics over time. In synopsis, the results strongly support the proper 
functioning of this transgenic Egr-1-luc murine model. The data supports 
the functionality of this model to observe the in-vivo Egr-1 promoter 
activity over time in the same animal. 
 
4.1 The Egr-1-luc murine model 
 
The Egr-1-luc murine model has been characterized as a novel model 
allowing the in vivo study of Egr-1 promoter activity and therefore protein 
expression and kinetics over time. The BLI of adult mice showed the 
highest signal intensities in the lip, snout, ears and paw regions (Fig. 9). 
It can be postulated that these anatomical regions are still undergoing 
more developmental changes, such as the continued growth of teeth, of 
tendons in the extremities or of outer ear tissue, than other areas of the 
body. Indeed, Egr-1 has been previously identified to be involved in 
periodontal regeneration (Ivanovski, Lichanska et al. 2007) and 
embryonic tendon formation (Lejard, Blais et al. 2011). While Egr-1 has 
to be determined further, an involvement of Egr-1 in the continued 
growth of the outer ear tissue in 4-month-old mice seems likely. My 
results show that a functional luciferases protein product is expressed as 
expected and the quantitative and qualitative measurement of the 
luciferase luminescence yields satisfactory results in the Egr-1-luc 
transgenic mouse model. In the remaining fur covered regions of the 
animal, little to no luciferase signal was detected. Due to the fact that this 
transgenic model was constructed of C57BL6 background, this absence of 
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signal could be in part due to quenching effects. The mouse lineage used 
is covered by a thick dark fur, which could obliterate the detection of 
photons emitted from underlying cells. To account for this possibility and 
to minimize the possibility of quenching effects, BLI and quantitative 
measurements of luciferases signals for all experiments are designed to 
be carried out only on areas covered by no or very little fur. In addition to 
the in vivo experiments, the luminescence measurements of SMC cultures 
proved that primary cells from the transgenic Egr-1-luc mouse model are 
also suitable for in vitro studies. 
 
4.2 Cell culture studies 
	  
The results of luciferase activity in vitro obtained in the SMC cultures, 
demonstrate the Egr-1 promoter activity in proliferating in vitro cultures 
of SMC and point to the functions of Egr-1 in vasculature (J.I.Pagel 2010) 
These results are in line with Egr-1 activities described in the literature for 
SMC (Fahmy and Khachigian 2007). As the major aim of this work was to 
monitor Egr-1 activity in vivo, I pursued the in vitro cultures not further.	  
 
4.3 Developmental studies 
 
It has previously been shown that tumor necrosis factor α (TNF α) and 
VEGF have both induced Egr-1 expression in endothelial cells 
(Mechtcheriakova, Schabbauer et al. 2001). In our developmental 
experiments, Egr-1 promoter activity was observed to be highest at day 7 
after birth, the earliest time point measured and to decrease rapidly in 
the following days until reaching a much lower baseline level at day 21. 
VEGFR-2 promoter controlled luciferase expression was analyzed in a 
similar way in neonatal mice (Zhang, Fang et al. 2004): At the earliest 
time point measured in those experiments at 2 weeks after birth highest 
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luciferase activity was found throughout the entire body, whereas in mice 
6 weeks of age the signal was about 100-fold reduced and remained 
constant for up to 15 weeks after birth. Due to our results, it is likely that 
there appears to be a spatial and temporal correlation between VEGF and 
Egr-1 activity during neonatal development. In our study, Egr-1 promoter 
controlled luciferase activity reached baseline levels already three weeks 
after birth indicating a faster decrease then for VEGFR-2. In vitro studies 
showed the interconnection of VEGF and Egr-1, as in endothelial cells 
VEGF stimulation led to initially high Egr-1 levels (Cao, Mahendran et al. 
1993). Besides VEGF, other growth factors up-regulated in neonatal 
organism, like FGF-1 and -2 can activate Egr-1 (Damon, Lange et al. 
1997), whereas the decrease in Egr-1 activity can be explained by the 
negative feedback loop of Egr-1, which can bind to the EBS sites located 
within its own promoter region (Cao, Mahendran et al. 1993) leading to a 
‘fine tuning’ of its activity. Apparently Egr-1 is involved in the cell 
proliferation process during postnatal growth and decreases in the adult. 
The activity of Egr-1 is on a high level almost all over the entire ventral 
anatomy of the neonatal mouse and decreases - seemingly simultaneous 
to the growth rate - until reaching a baseline activity when mice are fully 
grown and cell proliferation reaches a relatively low baseline value. During 
this stage, the only significant Egr-1 activity was observed at the paws, 
snout, ears, and tail, which is in line with observation measuring VEGFR-2 
promoter driven luciferase (Zhang, Fang et al. 2004). It still has to be 
determined which specific processes are taking place on these sites of 
high Egr-1 promoter activity relative to the rest of the body. 
The pattern of Egr-1 promoter activity (developing limbs, central nervous 
system, mandibles) is at least in part similar to the pattern of ERK 
signaling during embryogenesis, were major sites of ERK activity were 
observed, besides others, in limb buds, the forebrain and fronto-nasal 
processes (Corson, Yamanaka et al. 2003). This expression pattern 
observed points at the interconnection between ERK and Egr-1 signaling. 
The data clearly demonstrates that Egr-1 is highly up regulated 
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throughout the body during neonatal development, where I observed 
maximal activity at day seven after birth, the earliest time point 
measured. Similar observations were made with transgenic mice 
expressing VEGF promoter driven luciferase in neonatal mice (Faley, 
Takahashi et al. 2007). Also here maximal activity was observed one 
week after birth followed by a continuous decline in activity further on. 
When stimulating endothelial cells in vitro with VEGF, TNFα or thrombin, 
activation of Egr-1 was observed (Suehiro, Hamakubo et al. 2010). I 
supplemented our developmental experiments with immunohistochemical 
analyses of several tissues of the mice embryo to further validate the 
data obtained from BLI further. Here, the luciferase and Egr-1 staining of 
hind limb and masticatory tissues showed that protein expression for both 
were in accordance with the BLI data. 
 
4.4 Liver regenerating studies 
 
The involvement of Egr-1 in liver regeneration was first described by 
Müller and colleagues (Mueller, Broering et al. 2002), and Egr-1 knockout 
mice showed significantly delayed liver regeneration after hepatectomy 
(Liao, Shikapwashya et al. 2004). The importance of Egr-1 expression in 
liver injury has also been described in ethanol induced fatty liver, where 
Egr-1 promoted TNFα expression (McMullen, Pritchard et al. 2005). It was 
previously shown, that liver regeneration after partial hepatectomy is 
decreased in Egr-1 deficient mice because of impaired progression of 
mitosis, due to missing Egr-1–regulated expression of cell division cycle 
protein 20 homolog (Cdc20) (Liao, Shikapwashya et al. 2004). In our liver 
regeneration experiment, we have demonstrated that Egr-1 promoter 
driven luciferase expression was induced at the early stages of liver 
regeneration. After only 12 hours from surgery mRNA levels of luciferase 
and Egr-1 were already strongly elevated, which is in line with results 
obtained in rats (Mueller, Broering et al. 2002). Interestingly, luciferase 
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activity and protein level were both elevated at 48 h after surgery. 
During the regeneration of liver tissue, quiescent liver cells reenter the 
cell cycle and divide until the original liver mass is restored (Fausto, 
Campbell et al. 2006). Besides the profound induction of proliferation, 
partial hepatectomy leads to local hypoxia in the ischemic stump left after 
excision. This effect has been shown by the up-regulation of hypoxia 
inducible factor 1 (HIF-1) (Maeno, Ono et al. 2005), which is closely 
associated with the presence of tissue hypoxia. In those experiments it 
was observed that the levels of HIF-1α peaked at 24 h after surgery, 
whereas the peak levels of VEGF appeared only at later time points. 
Hence, the induction of Egr-1 after partial hepatectomy can, in addition to 
the stimulation of liver cells to proliferate, also be in part due to hypoxic 
conditions, an effect that has been described previously (Yan, Lu et al. 
1999; Nishi, Nishi et al. 2002; Liao, Shikapwashya et al. 2004). This 
same effect has also already been described for macrophages in vitro, 
where hypoxia induced Egr-1 expression occurred after hypoxic treatment 
(Elbarghati, Murdoch et al. 2008). 
Even though the major Egr-1 promoter activity was observed in the area 
of the initial surgery wound, which is mainly due to the wound healing 
processes and hypoxic conditions, some elevated activity was visible at 
the edges of the remaining lobes suggesting the onset tissue regeneration 
by the means of cell division and proliferation. These results support the 
reported findings of impaired mitosis in Egr-1 deficient mice (Liao, 
Shikapwashya et al. 2004) and evidence that Egr-1 is not only induced 
within the healing process, but also during other processes where cell 
division and proliferation are involved. 
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4.5 Wound healing studies 
 
At the early stages of wound healing, an inflammatory response followed 
by re-epithelialization of the wound area and establishment of granulation 
tissue with accompanying neovascularization occurs (Clark 1993). Due to 
the interaction of Egr-1 and inflammatory parameters, like TNFα 
(McMullen, Pritchard et al. 2005; Rockel, Bernier et al. 2009; Rockel, Grol 
et al. 2009) and others, Egr-1 is involved in the wound healing process. 
In Egr-1 deficient mice wound healing, immune response and the influx of 
inflammatory cells was significantly reduced, whereas Egr-1 
overexpression led in turn to exuberant tissue repair and enhanced 
collagen production (Wu, Melichian et al. 2009). The wound healing 
experiments are thus extremely suitable to show the functionality of the 
Egr-1-luc transgenic mouse model. The data of the ear wound experiment 
confirms in vivo that Egr-1 indeed is playing a major role in the 
inflammatory response and the wound healing process. Its activity in the 
tissue surrounding the immediate wound area was found to be increased 
by >12-fold whereas Egr-1 expression in tissue more distant to the 
wound remained unaltered. 
 
	   60	  
5 Summary and Outlook 
	  
5.1 Summary 
 
In summary, the present study shows that the observation of luciferase 
activity, which is congruent with Egr-1-promoter activity over time in the 
living transgenic Egr-1-luc animal model allows gaining a view of the 
spatial expression pattern of luc and their changes over time in vivo. The 
results confirm the ubiquitous role of Egr-1 in proliferation, regeneration, 
wound healing and development. The present study monitored the Egr-1 
activation pattern over time in transgenic mice expressing Egr-1 promoter 
driven luciferase and showed the spatial expression pattern and their time 
dependent change in vivo. This transgenic mouse provides a convenient 
model for studying Egr-1 expression during neonatal development and 
wound healing at areas were the fur of mice with C57/bl6 background 
does not interfere with BLI imaging. In neonatal mice, high overall Egr-1 
promoter activity was observed, which reached basal levels three weeks 
after birth with residual activity remaining at snout, ears and paws. In 
wound healing, Egr-1 promoter activity was highly up regulated at the 
site of injury. 
Monitoring Egr-1 activity within internal organs, such as in the liver 
regeneration model presented, was only possible by endpoint 
measurements with animals having an opened body cavity. Here it was 
observed, that Egr-1 promoter activity and Egr-1 mRNA levels were 
increased in the regenerating liver after partial hepatectomy. 
In summary, this mouse model allows real time in vivo imaging of Egr-1 
promoter activity during development, tissue regeneration and wound 
healing in vivo and in vitro measurement of Egr-1 promoter activity in 
SMC cell cultures. 
To further improve its usability for BLI, crossbreeding into hairless mice 
will result in a further improvement of its sensitivity by decreasing 
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quenching effects of the fur. Moreover, BLI will then offer a useful tool for 
monitoring the tissue-specific effects of pharmaceutical drugs over time in 
vivo, too. This can be especially useful for the development of 
chemotherapeutic agents binding to certain cancer-specific proteins for 
example. 
 
5.2 Outlook 
 
Due to the advances of genetic engineering in organisms, the use of 
luciferase reporters became a useful monitoring tool to a wide range of 
applications and allows the real-time in vivo measurement of biologic 
processes. Since dynamic changes over time cannot be examined by end-
point measurements, studying Egr-1 activity within the living organism 
will aid to gain new information on in vivo Egr-1 gene activation. One of 
the major advantages, which the use of non invasive measurements using 
luciferase reporters offer, is that biological changes can be observed in 
the same animals over a period of time without the absolute need to 
sacrifice the animals. 
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5.3 Zusammenfassung 
 
Zusammenfassend zeigt die vorliegende Arbeit, dass das Egr-1-luc 
Tiermodell geeignet ist räumliche Egr-1 Expressionsmuster über eine 
Zeitspanne hinweg am lebenden Organismus in vivo qualitativ und 
quantitativ zu beobachten. Die Ergebnisse bestätigen die allgegenwärtige 
Rolle von Egr-1 bei der Proliferation, Regeneration, Wundheilung und 
Entwicklung. Diese Arbeit verfolgte das Egr-1 Aktivierungsmuster in 
transgenen Mäusen mittels der von dem Egr-1 Promoter kontrollierten 
Luciferase über verschiedene Zeitspannen hinweg und zeigt das räumliche 
Expressionsmuster und dessen Änderung im Zeitverlauf in vivo. Diese 
transgene Egr-luc Maus ist somit ein geeignetes Modell um die Egr-1-
Expression während der Entwicklung von neugeborenen Tiere und der 
Wundheilung an Bereichen, an denen das Fell der Tiere mit C57/BL6 
Hintergrund nicht die BLI Bildgebung stört, zu beobachten. In 
neugeborenen Mäusen (7. Lebenstag) wurde eine insgesamt hohe Egr-1-
Promotor-Aktivität beobachtet, welche bis zum 21. Tag nach Geburt 
kontinuierlich auf ein Basallevel mit einer Restaktivität an Schnauze, 
Ohren und Pfoten abnahm. Bei der Wundheilung wurde eine stark 
hochregulierte Egr-1-Promotor-Aktivität in der unmittelbaren Umgebung 
der Verletzung nach 24 Stunden gezeigt. Die Beobachtung der Egr-1-
Aktivität an der Oberfläche innerer Organe, wie in dem hier vorgestellten 
Modell der Leberregeneration, war lediglich durch End-Point-Messungen 
möglich, da die Körperhöhle der Tiere hierzu eröffnet werden musste. In 
diesem Experiment wurde beobachtet, dass die Egr-1-Promotor-Aktivität 
und die Egr-1 mRNA-Spiegel in der regenerierenden Leber nach partieller 
Hepatektomie erhöht waren. Zusammenfassend erlaubt die Egr-luc Maus 
eine in vivo Bildgebung der Egr-1-Promotor-Aktivität während der 
Entwicklung, der Geweberegeneration und Wundheilung in Echtzeit und 
die in vitro Messung der Egr-1 Promoter Aktivität in SMC Zellkulturen. Zu 
einer weiteren Verbesserung dieses Modells für BLI könnten Kreuzungen 
mit haarlosen Mäusen führen und die Sensitivität dieses Modells für BLI - 
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durch die Verminderung von Signalauslöschung durch das Fell - weiter 
verbessern. Es ist weiterhin zu erwarten, dass BLI dann auch zur in vivo 
Beobachtung der gewebsspezifischen Wirkungen von Pharmazeutika im 
Zeitverlauf eingesetzt werden könnte. Dies kann zum Beispiel bei der 
Entwicklung von Pharmazeutika in der Chemotherapie, die an bestimmte 
Karzinom-spezifische Proteine binden, besonders nützlich sein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   64	  
6 Appendix 
	  
6.1 Abbreviations  
 
ALI  acute lung injury 
AMP  adenosine mono phosphate 
AP1  activated protein-1 responsive element 
ATP  adenosine tri phosphate 
BLI  body luminescence imaging 
bp  base pair 
cAMP  cyclic adenosine mono phosphate 
CBP  cAMP response element binding protein 
CCD  cooled charge-coupled device 
Cdc20 cell division cycle protein 20 
cDNA  complementary DNA 
CMF  chicken embryo fibroblasts 
CMV  cytomegalovirus 
CoA  coenzyme A 
COPD  chronic obstructive pulmonary disease 
C-terminus carboxy-terminus 
DTT  dithiothreitol 
DNA  deoxyribonucleic acid 
EBS  Egr-1 binding sequence 
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EDTA  ethylene diamine tetra-acetic acid 
Egr  early growth response 
ERK  extracellular regulated kinase 
FCS  fetal calf serum 
FGF  fibroblast growth factor 
Fig.  figure 
g  gram 
g  standard gravity (=9,806 m/s2) 
h  hour  
HCl  hydrochloric acid 
HIF  hypoxia inducible factor 
HIV  human immunodeficiency virus 
HRP  horseradish peroxidase  
HSV  herpes simplex virus 
i.p.  intra-peritoneal 
ICAM  intercellular adhesion molecule 
Il  inter-leucine 
kDa  kilo Dalton 
LAR  luciferases assay reagent 
LCI  luciferase complementation imaging 
LED  light-emitting diode 
Luc  luciferases 
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MHV  mouse hepatitis virus 
min  minute 
mm  millimeter 
MMP  matrix metalloproteinase 
mRNA messenger ribonucleic acid 
n  number 
Nab  NGFI-A binding protein 
N-terminus amino-terminus 
nm  nanometer 
NGF  nerve growth factor 
NGFI-A nerve growth factor inducible A 
NLS  nuclear localization signal 
N-terminus Amino-terminus 
PBS  phosphate-buffered saline 
PCR  polymerase chain reaction 
PDGF  platelet derived growth factor 
PFA  paraformaldehyde 
qRT-PCR quantitative real time polymerase chain reaction 
RLU  relative light units 
RNA  ribonucleic acid 
ROI  regions of interest 
Rpm  rounds per minute 
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rRNA  ribosomal RNA 
RT-PCR real-time polymerase chain reaction 
sec  second 
SMC  smooth muscle cells 
SRE  serum response element 
TBS  tris buffered saline 
TNFα  tumor necrosis factor α 
TRE  thiophorbolester responsive element 
tRNA  total ribonucleic acid 
UV  ultraviolet 
VEGF  vascular endothelial growth factor 
VEGFR vascular endothelial growth factor receptor 
ZENK  zif268, egr-1, NGFI-A, krox24 
Zif  zinc finger 
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